Infliximab therapy efficacy and persistence at a Canadian academic centre despite a change in access procedure

Clinical Rheumatology

Volumn 31, Issue 2, 2012, Pages 211-217

  Barnabe, Cheryl ^a   Barr, Susan G ^b   Martin, Liam ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Drug toxicity; Infliximab; Pharmacovigilance; Rheumatoid arthritis; Survival rate; Switch treatment

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; CYCLOSPORIN; ETANERCEPT; GOLD; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CANADA; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FATALITY; DRUG PROGRAM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY FAILURE; RHEUMATOID ARTHRITIS; SKIN MANIFESTATION; SURVIVAL; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CANADA; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHARMACOVIGILANCE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84856711205     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-011-1803-5     Document Type: Article

References (52)

1. SK Agarwal AL Maier LB Chibnik JS Coblyn A Fossel R Lee, et al. 2005 Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center Arthritis Rheum 53 6 872 878 16342095 10.1002/art.21582 1:CAS:528:DC%2BD28Xks1WhsA%3D%3D (Pubitemid 41811128)
2. AM Bertoli I Strusberg M Baravalle Z Betelu D Calas L Morales, et al. 2008 Rate and causes of infliximab discontinuation in patients with rheumatoid arthritis in a private clinical practice J Clin Rheumatol 14 6 313 317 18690164 10.1097/RHU.0b013e31817a7e0e
3. O Brocq CH Roux C Albert V Breuil N Aknouche S Ruitord, et al. 2007 TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease Joint Bone Spine 74 2 148 154 17368068 10.1016/j.jbspin.2006.06.011 1:CAS:528:DC%2BD2sXms1Srsbw%3D (Pubitemid 46603027)
4. L Carmona JJ Gomez-Reino BIOBADASER Group 2006 Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER Arthritis Res Ther 8 3 R72 16620398 10.1186/ar1941
5. V Ducoulombier E Solau P Coquerelle E Houvenagel JL Siame X Desprez, et al. 2007 Long-term results of infliximab therapy in rheumatoid arthritis: experience acquired by the North-Pas-de-Calais hospital network Joint Bone Spine 74 1 56 59 17182267 10.1016/j.jbspin.2006.03.008 1:CAS:528:DC%2BD2sXkt1Srtrk%3D
6. M Flendrie MC Creemers PM Welsing AA den Broeder PL van Riel 2003 Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis Ann Rheum Dis 62 Suppl 2 ii30 ii33 14532145 1:CAS:528:DC%2BD3sXpvVyjtL4%3D
7. MS Heiberg W Koldingsnes K Mikkelsen E Rodevand C Kaufmann P Mowinckel, et al. 2008 The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study Arthritis Rheum 59 2 234 240 18240258 10.1002/art.23333 1:CAS:528:DC%2BD1cXjt1yqs7g%3D (Pubitemid 351272960)
8. ML Hetland IJ Christensen U Tarp L Dreyer A Hansen IT Hansen, et al. 2010 Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry Arthritis Rheum 62 1 22 32 20039405 10.1002/art.27227 1:CAS:528:DC%2BC3cXhtFGnurnP
9. A Marchesoni E Zaccara R Gorla C Bazzani P Sarzi-Puttini F Atzeni, et al. 2009 TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice Ann N Y Acad Sci 1173 837 846 19758236 10.1111/j.1749-6632.2009.04621.x 1:CAS:528: DC%2BD1MXhtlCnt7vO
10. SM Du Pan S Dehler A Ciurea HR Ziswiler C Gabay A Finckh, et al. 2009 Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis Arthritis Rheum 61 5 560 568 19405000 10.1002/art.24463
11. R Stern F Wolfe 2004 Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis J Rheumatol 31 8 1538 1545 15290732 1:CAS:528:DC%2BD2cXnt1emu7Y%3D (Pubitemid 39006634)
12. PV Voulgari Y Alamanos SN Nikas DV Bougias TI Temekonidis AA Drosos 2005 Infliximab therapy in established rheumatoid arthritis: an observational study Am J Med 118 5 515 520 15866254 10.1016/j.amjmed.2005.01.029 1:CAS:528:DC%2BD2MXjvVOiu74%3D (Pubitemid 40615475)
13. HB Oei RS Hooker DJ Cipher A Reimold 2009 High rates of stopping or switching biological medications in veterans with rheumatoid arthritis Clin Exp Rheumatol 27 6 926 934 20149307 1:STN:280:DC%2BC3c7gt12quw%3D%3D
14. IT Figueiredo J Morel J Sany B Combe 2008 Maintenance and tolerability of infliximab in a cohort of 152 patients with rheumatoid arthritis Clin Exp Rheumatol 26 1 18 23 18328142 1:STN:280:DC%2BD1c7ntVehsA%3D%3D (Pubitemid 351385251)
15. N Neven M Vis AE Voskuyl GJ Wolbink MT Nurmohamed BA Dijkmans, et al. 2005 Adverse events in patients with rheumatoid arthritis treated with infliximab in daily clinical practice Ann Rheum Dis 64 4 645 646 15769924 10.1136/ard.2004.028597 1:STN:280:DC%2BD2M7jslGgsg%3D%3D (Pubitemid 40469101)
16. R Westhovens D Yocum J Han A Berman I Strusberg P Geusens, et al. 2006 The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial Arthritis Rheum 54 4 1075 1086 16572442 10.1002/art.21734 1:CAS:528:DC%2BD28XksVyht7s%3D (Pubitemid 43672920)
17. WG Dixon K Watson M Lunt KL Hyrich AJ Silman DP Symmons, et al. 2006 Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register Arthritis Rheum 54 8 2368 2376 16868999 10.1002/art.21978 1:CAS:528: DC%2BD28XpsFGgu7g%3D (Pubitemid 44204996)
18. G Gartlehner RA Hansen BL Jonas P Thieda KN Lohr 2006 The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis J Rheumatol 33 12 2398 2408 17225293 1:CAS:528:DC%2BD2sXhtVCntbk%3D (Pubitemid 46067817)
19. T Bongartz AJ Sutton MJ Sweeting I Buchan EL Matteson V Montori 2006 Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials JAMA 295 19 2275 2285 16705109 10.1001/jama.295.19.2275 1:CAS:528:DC%2BD28Xksl2ktrk%3D (Pubitemid 43736578)
20. B Haraoui E Keystone 2006 Musculoskeletal manifestations and autoimmune diseases related to new biologic agents Curr Opin Rheumatol 18 1 96 100 16344625 (Pubitemid 43740411)
21. HH Lee IH Song M Friedrich A Gauliard J Detert J Rowert, et al. 2007 Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists Br J Dermatol 156 3 486 491 17300238 10.1111/j.1365-2133.2007.07682.x 1:CAS:528:DC%2BD2sXjvVKksLw%3D
22. J Askling E Baecklund F Granath P Geborek M Fored C Backlin, et al. 2009 Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish biologics register Ann Rheum Dis 68 5 648 653 18467516 10.1136/ard.2007.085852 1:CAS:528:DC%2BD1MXls1Churg%3D
23. SB Cohen P Emery MW Greenwald M Dougados RA Furie MC Genovese, et al. 2006 Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks Arthritis Rheum 54 9 2793 2806 16947627 10.1002/art.22025 1:CAS:528:DC%2BD28XhtFWksLjI (Pubitemid 44497758)
24. P Emery E Keystone HP Tony A Cantagrel R van Vollenhoven A Sanchez, et al. 2008 IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial Ann Rheum Dis 67 11 1516 1523 18625622 10.1136/ard.2008.092932 1:CAS:528:DC%2BD1cXhtl2gsbbI
25. MC Genovese M Schiff M Luggen JC Becker R Aranda J Teng, et al. 2008 Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy Ann Rheum Dis 67 4 547 554 17921185 10.1136/ard.2007.074773 1:CAS:528:DC%2BD1cXltlSksrg%3D (Pubitemid 351498439)
26. JS Smolen J Kay MK Doyle R Landewe EL Matteson J Wollenhaupt, et al. 2009 Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial Lancet 374 9685 210 221 19560810 10.1016/S0140-6736(09)60506-7 1:CAS:528:DC%2BD1MXos12ru7o%3D
27. K Malottki P Barton A Tsourapas A Uthman Z Liu K Routh, et al. 2011 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation Health Technol Assess 15 14 1 278 21439251 1:STN:280:DC%2BC3MzgtlWkuw%3D%3D
28. E Solau-Gervais N Laxenaire B Cortet S Dubucquoi B Duquesnoy RM Flipo 2006 Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody Rheumatology (Oxford) 45 9 1121 1124 10.1093/rheumatology/kel054 1:CAS:528:DC%2BD28XhtVWlt7fJ (Pubitemid 44542100)
29. KL Hyrich M Lunt KD Watson DP Symmons AJ Silman British Society for Rheumatology Biologics Register 2007 Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study Arthritis Rheum 56 1 13 20 17195186 10.1002/art.22331 1:CAS:528:DC%2BD2sXhsFaisrw%3D (Pubitemid 46106174)
30. E Hjardem M Ostergaard J Podenphant U Tarp LS Andersen J Bing, et al. 2007 Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? Ann Rheum Dis 66 9 1184 1189 17389656 10.1136/ard.2006.054742 1:CAS:528: DC%2BD2sXhtVKltL7J (Pubitemid 47309735)
31. KE Hansen JP Hildebrand MC Genovese JJ Cush S Patel DA Cooley, et al. 2004 The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis J Rheumatol 31 6 1098 1102 15170921 1:CAS:528: DC%2BD2cXlsFWgtrY%3D (Pubitemid 38715884)
32. JJ Gomez-Reino L Carmona BIOBADASER Group 2006 Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period Arthritis Res Ther 8 1 R29 16507128 10.1186/ar1881
33. AR Erickson TR Mikuls 2007 Switching anti-TNF-alpha agents: what is the evidence? Curr Rheumatol Rep 9 5 416 420 17915098 10.1007/s11926-007-0066-2 1:CAS:528:DC%2BD2sXht1WmsrvN (Pubitemid 47597063)
34. O Brocq C Albert C Roux D Gerard V Breuil LE Ziegler 2004 Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy: experience with 18 patients Joint Bone Spine 71 6 601 603 15589452 10.1016/j.jbspin.2004.07.009 1:STN:280:DC%2BD2M%2FhsFWltA%3D%3D (Pubitemid 39626739)
35. M Blom W Kievit J Fransen IH Kuper AA den Broeder CM De Gendt, et al. 2009 The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis J Rheumatol 36 10 2171 2177 19723902 10.3899/jrheum.090054 1:CAS:528:DC%2BD1MXhsVams7bP
36. S Alivernini A Laria E Gremese A Zoli G Ferraccioli 2009 ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature Arthritis Res Ther 11 6 R163 19886983 10.1186/ar2848
37. A Finckh A Ciurea L Brulhart B Moller UA Walker D Courvoisier, et al. 2010 Which subgroup of rheumatoid arthritis patients benefits from switching to rituximab versus alternative anti-TNF agents after previous failure to anti-TNF agent? Ann Rheum Dis 69 2 387 393 19416802 10.1136/ard.2008.105064 1:CAS:528:DC%2BC3cXitlKrtrY%3D
38. A Finckh A Ciurea L Brulhart D Kyburz B Moller S Dehler, et al. 2007 B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents Arthritis Rheum 56 5 1417 1423 17469098 10.1002/art.22520 (Pubitemid 46764068)
39. SG Barr L Martin C Chung WP Maksymowych 2004 Mandatory pharmacosurveillance-a Canadian model for access to therapy and research Clin Exp Rheumatol 22 5 Suppl 35 S39 S43 15552513 1:STN:280:DC%2BD2crns1ajtQ%3D%3D
40. KL Hyrich KD Watson M Lunt DP Symmons British Society for Rheumatology Biologics Register (BSRBR) 2011 Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008 Rheumatology (Oxford) 50 1 117 123 10.1093/rheumatology/keq209 1:CAS:528:DC%2BC3cXhsFGkur%2FL
41. ML Hetland HM Lindegaard A Hansen J Podenphant J Unkerskov VS Ringsdal, et al. 2008 Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO registry Ann Rheum Dis 67 7 1023 1026 18272669 10.1136/ard.2007.087262 1:STN:280:DC%2BD1czot1yitw%3D%3D (Pubitemid 351956667)
42. ML Prevoo MA van 't Hof HH Kuper MA van Leeuwen LB van de Putte PL van Riel 1995 Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis Arthritis Rheum. 38 1 44 48 7818570 10.1002/art.1780380107 1:STN:280:DyaK2M7hvVeqtA%3D%3D
43. DT Felson JJ Anderson M Boers C Bombardier D Furst C Goldsmith, et al. 1995 American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis Arthritis Rheum 38 6 727 735 7779114 10.1002/art.1780380602 1:STN:280:DyaK2M3pvVSmtA%3D%3D
44. B Bruce JF Fries 2005 The health assessment questionnaire (HAQ) Clin Exp Rheumatol 23 5 Suppl 39 S14 S18 16273780 1:STN:280:DC%2BD2MrpsV2ksw%3D%3D
45. A Finckh JF Simard C Gabay PA Guerne SCQM physicians 2006 Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis Ann Rheum Dis 65 6 746 752 16339288 10.1136/ard.2005.045062 1:CAS:528:DC%2BD28XlvVSkt7g%3D (Pubitemid 43799173)
46. LE Kristensen T Saxne JA Nilsson P Geborek 2006 Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden Arthritis Res Ther 8 6 R174 17121678 10.1186/ar2084
47. B Tang M Rahman HC Waters P Callegari 2008 Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis Clin Ther 30 7 1375 1384 18691998 10.1016/S0149-2918(08)80063-X 1:CAS:528: DC%2BD1MXltVyiu78%3D
48. M Duclos L Gossec A Ruyssen-Witrand C Salliot M Luc S Guignard, et al. 2006 Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients J Rheumatol 33 12 2433 2438 17014004 1:CAS:528: DC%2BD2sXhtVCnur8%3D
49. GM Bartelds CA Wijbrandts MT Nurmohamed S Stapel WF Lems L Aarden, et al. 2010 Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study Ann Rheum Dis 69 5 817 821 19581278 10.1136/ard.2009.112847 1:CAS:528:DC%2BC3cXntlOks7w%3D
50. N Emi Aikawa JF de Carvalho C Artur Almeida Silva E Bonfa 2010 Immunogenicity of anti-TNF-alpha agents in autoimmune diseases Clin Rev Allergy Immunol 38 2-3 82 9 19565360 10.1007/s12016-009-8140-3 1:CAS:528: DC%2BC3cXktVCgurY%3D
51. TR Radstake M Svenson AM Eijsbouts FH van den Hoogen C Enevold PL van Riel, et al. 2009 Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis Ann Rheum Dis 68 11 1739 1745 19019895 10.1136/ard.2008. 092833 1:CAS:528:DC%2BD1MXhs1WitbfP
52. Pascual-Salcedo D, Plasencia C, Ramiro S, Nuno L, Bonilla G, Nagore D et al (2011) Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) doi: 10.1093/rheumatology/ker124